10:20 AM EDT, 04/05/2024 (MT Newswires) -- Bristol-Myers Squibb ( BMY ) and 2seventy bio (TSVT) said Friday that the US Food and Drug Administration has approved the expansion of the indication of the companies' myeloma treatment Abecma.

The approval makes Abecma available to adult patients with triple class-exposed relapsed or refractory multiple myeloma following two or more previous lines of therapy, the companies said.

They said that the FDA's approval was based on results from a phase 3 trial that assessed Abecma compared with standard regimens for relapsed or refractory multiple myeloma.

Bristol-Myers was 0.8% lower while 2seventy bio climbed more than 15% in recent trading.

Price: 51.01, Change: -0.40, Percent Change: -0.77